Evidence map›Paper›PMID 28487386›Full record

ArticleCancer research2017

An miRNA Expression Signature for the Human Colonic Stem Cell Niche Distinguishes Malignant from Normal Epithelia.

Vignesh Viswanathan, Shirish Damle, Tao Zhang, Lynn Opdenaker, Shirin Modarai, Monica Accerbi, Skye Schmidt, Pamela Green, Deni Galileo, Juan Palazzo and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Vignesh ViswanathanCenter for Translational Cancer Research, Helen F Graham Cancer Center and Research Institute, Newark, Delaware.
Shirish DamleThomas Jefferson University and Kimmel Cancer Center, Philadelphia, Pennsylvania.
Tao ZhangCenter for Translational Cancer Research, Helen F Graham Cancer Center and Research Institute, Newark, Delaware.
Lynn OpdenakerCenter for Translational Cancer Research, Helen F Graham Cancer Center and Research Institute, Newark, Delaware.
Shirin ModaraiCenter for Translational Cancer Research, Helen F Graham Cancer Center and Research Institute, Newark, Delaware.
Monica AccerbiDepartment of Plant and Soil Sciences, Delaware Biotechnology Institute, Newark, Delaware.
Skye SchmidtDepartment of Plant and Soil Sciences, Delaware Biotechnology Institute, Newark, Delaware.
Pamela GreenDepartment of Plant and Soil Sciences, Delaware Biotechnology Institute, Newark, Delaware.
Deni GalileoDepartment of Biological Sciences, University of Delaware, Newark, Delaware.
Juan PalazzoThomas Jefferson University and Kimmel Cancer Center, Philadelphia, Pennsylvania.
Jeremy FieldsCA*TX Inc., Gladwyne, Pennsylvania.
Sepehr HaghighatCenter for Translational Cancer Research, Helen F Graham Cancer Center and Research Institute, Newark, Delaware.
Isidore RigoutsosThomas Jefferson University and Kimmel Cancer Center, Philadelphia, Pennsylvania.
Greg GonyeThomas Jefferson University and Kimmel Cancer Center, Philadelphia, Pennsylvania.
Bruce M BomanCenter for Translational Cancer Research, Helen F Graham Cancer Center and Research Institute, Newark, Delaware. BrBoman@ChristianaCare.org.
Sidney Kimmel Cancer Center · USUniversity of Delaware · USCenter for Cancer Research · USBeth Israel Deaconess Medical Center · USNanostring Technologies (United States) · USTeradyne (United States) · US

Funding

Predictive Modeling & Optimal Control Framework for Model-Based Epidemic Response in DelawareP20GM103446 · NIGMS · UNIVERSITY OF DELAWARE · PI Anjana Narayan Bhat · 2012 to 2026
$67.2M
VOLUMETRIC BREAST DENSITY ESTIMATION USING BREAST SURFACE RECONSTRUCTEDP20RR016472 · NCRR · UNIVERSITY OF DELAWARE · PI STANHOPE, STEVEN J. · 2001 to 2011
$37.6M
Global Analysis of the Human RNA DegradomeR01GM096471 · NIGMS · UNIVERSITY OF DELAWARE · PI GREEN, PAMELA J. · 2010 to 2014
$2.3M
NCRR NIH HHS P20 RR016472NIGMS NIH HHS P20 GM103446NIGMS NIH HHS R01 GM096471
6 · The paper itself

Abstract

Malignant transformation of tissue stem cells (SC) may be the root of most cancer. Accordingly, we identified miRNA expression patterns in the normal human colonic SC niche to understand how cancer stem cells (CSC) may arise. In profiling miRNA expression in SC-enriched crypt subsections isolated from fresh, normal surgical specimens, we identified 16 miRNAs that were differentially expressed in the crypt bottom, creating an SC signature for normal colonic epithelia (NCE). A parallel analysis of colorectal cancer tissues showed differential expression of 83 miRNAs relative to NCE. Within the 16 miRNA signature for the normal SC niche, we found that miR-206, miR-007-3, and miR-23b individually could distinguish colorectal cancer from NCE. Notably, miR-23b, which was increased in colorectal cancer, was predicted to target the SC-expressed G protein-coupled receptor LGR5. Cell biology investigations showed that miR-23b regulated CSC phenotypes globally at the level of proliferation, cell cycle, self-renewal, epithelial-mesenchymal transition, invasion, and resistance to the colorectal cancer chemotherapeutic agent 5-fluorouracil. In mechanistic experiments, we found that miR-23b decreased LGR5 expression and increased ALDH

Indexed as

Cell Line, TumorCell ProliferationColorectal NeoplasmsHumansIntestinal MucosaMicroRNAsNeoplastic Stem CellsStem Cell NicheMicroRNAs

Identifiers

PMID28487386
PMCPMC13191046
OpenAlexW2612730407

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.